Altre lingue Biomea Fusion, Inc.

Azioni

BMEA

US09077A1060

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 10/05/2024			Variaz. 5gg	Var. 1 gen.
10,65 ^USD	-6,91%		-10,73%	-26,65%

02/05	Biomea Fusion, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
02/04	Le azioni di Biomea Fusion scendono dopo il declassamento di JPMorgan	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights	02/05
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01/05
North American Morning Briefing : Powell Awaited -2-	03/04
Biomea Fusion Shares Decline Following JPMorgan Downgrade	02/04
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	02/04
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01/04
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219	01/04
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219	01/04
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	01/04
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	01/04
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle	07/03
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	06/03
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	06/03
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	04/03
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01/03
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference	09/01
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study with BMF-219	09/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Biomea Fusion, Inc.

Azioni

BMEA

US09077A1060

Altre lingue

Filtri